×
About 3,334 results

ALLMedicine™ Lennox-gastaut Syndrome Center

Research & Reviews  743 results

The role of surgery in the management of Lennox-Gastaut syndrome: A systematic review a...
https://doi.org/10.1111/epi.16851
Epilepsia Thirunavu V, Du R et. al.

Feb 24th, 2021 - Lennox-Gastaut syndrome (LGS) is a severe form of childhood onset epilepsy in which patients require multiple medications and may be candidates for palliative surgical intervention. In this meta-analysis, we sought to evaluate the impact of pallia...

The efficacy and tolerability of auto-stimulation-VNS in children with Lennox-Gastaut s...
https://doi.org/10.1016/j.seizure.2021.02.015
Seizure Abdelmoity SA, Abdelmoity AA et. al.

Feb 24th, 2021 - Lennox-Gastaut syndrome (LGS) is a severe drug-resistant epilepsy (DRE) of childhood. The Vagus Nerve Stimulator (VNS) is established as a safe and effective treatment for DRE. This study assesses efficacy and tolerability of the auto-stimulation ...

Cannabidiol in the Treatment of Epilepsy.
https://doi.org/10.1007/s40261-021-01003-y 10.1111/epi.12550 10.1056/NEJM200002033420503 10.1001/jamaneurol.2017.3949 10.1111/epi.12631 10.1016/S2215-0366(19)30401-8 10.1016/j.yebeh.2014.08.135 10.1016/j.yebeh.2016.11.006 10.1007/s11064-017-2287-8 10.1111/epi.12610 10.1016/j.yebeh.2019.106458 10.1016/j.yebeh.2015.02.043 10.1016/S1474-4422(15)00379-8 10.1056/NEJMoa1611618 10.1001/jamaneurol.2020.0073 10.1056/NEJMoa1714631 10.1016/S0140-6736(18)30136-3 10.1111/epi.13499 10.1111/epi.14670 10.1111/epi.14628 10.1016/j.eplepsyres.2019.03.015 10.1016/j.yebeh.2018.05.013 10.1177/0883073816669450 10.1016/j.yebeh.2020.106988 10.1007/s40263-018-0589-2 10.1073/pnas.1711351114 10.1089/can.2019.0005 10.1111/epi.14629 10.1016/j.yebeh.2019.04.008 10.1590/S1516-44462008000300015 10.1007/BF00432554 10.1177/0269881110379283 10.1038/npp.2011.6 10.2174/1871527313666140612114838 10.1016/j.pnpbp.2006.06.004 10.1177/0269881110389095 10.1016/j.euroneuro.2013.10.012 10.1016/j.nlm.2018.02.009 10.1007/s00213-012-2955-y 10.1007/s13311-015-0382-6 10.1176/appi.ajp.2017.17030325 10.1007/s00213-018-4885-9 10.1016/j.psyneuen.2018.03.009 10.3389/fpsyt.2019.00063 10.1016/j.yebeh.2018.07.027 10.1016/j.yebeh.2020.107558 10.1007/s40263-019-00624-4 10.1097/WNP.0000000000000633 10.3389/fneur.2019.01313 10.1016/j.yebeh.2019.106826 10.1038/s41598-019-44056-y 10.1016/j.seizure.2020.06.012 10.1080/09540261.2018.1474730 10.1124/dmd.32.11.1279 10.1002/cpdd.665 10.1111/epi.13060 10.1212/WNL.0000000000005254 10.1111/epi.16546 10.1097/FTD.0b013e31825dc4a6 10.1016/j.yebeh.2019.106459 10.1007/s40263-020-00726-4 10.1111/epi.13852 10.1111/epi.16071 10.1002/jcph.1634 10.1001/jama.2017.11909 10.1016/j.yebeh.2018.03.025
Clinical Drug Investigation; von Wrede R, Helmstaedter C et. al.

Feb 9th, 2021 - Anecdotal reports addressing the successful seizure treatment of severe epilepsies with cannabidiol (CBD) have increased both public interest and academic research. Placebo-controlled, randomized, controlled trials proved the efficacy of pharmaceu...

Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehen...
https://doi.org/10.1007/s11606-020-06504-8 10.1016/j.lfs.2005.09.011 10.1111/epi.12631 10.1016/j.pharmthera.2017.02.041 10.1016/j.phrs.2016.01.033 10.1016/0014-2999(82)90264-3 10.1016/j.pnpbp.2015.06.017 10.1016/j.lfs.2011.05.018 10.2174/1389200217666151210142051 10.1016/j.bcp.2005.07.007 10.1111/epi.13060 10.2174/157488611798280924 10.1073/pnas.0711278105 10.1073/pnas.1211204110 10.1073/pnas.1711351114 10.7717/peerj.153 10.3390/ijms19030833 10.1089/can.2016.0034 10.1097/j.pain.0000000000001464 10.1080/15622975.2017.1285049 10.1007/BF00421539 10.1038/clpt.1980.139 10.1124/dmd.111.041384 10.3851/IMP1953 10.1124/dmd.32.11.1279 10.1002/j.1875-9114.2012.01028.x 10.1002/cpdd.665 10.1007/s11910-018-0882-y 10.1111/j.2042-7158.1977.tb11378.x 10.1002/ptr.2625 10.1111/epi.13852 10.1016/j.yebeh.2019.07.008 10.1016/j.neuropharm.2019.107733 10.1089/can.2015.0012 10.1016/j.euroneuro.2019.09.430 10.1016/j.pnpbp.2018.06.002 10.1097/FBP.0000000000000119 10.1016/j.cbi.2019.108914 10.1097/ADM.0000000000000118 10.1007/BF00432554 10.1038/npp.2017.209 10.1038/npp.2009.184 10.1111/bph.13887 10.1111/bph.13333 10.1038/npp.2010.58 10.1016/j.euroneuro.2016.12.004 10.1111/bcp.13710 10.1111/bcpt.13152 10.1111/ajt.15398 10.3390/jcm8070989 10.3390/molecules24122256 10.1016/j.nbd.2016.06.013 10.1098/rstb.2012.0431 10.1016/j.lfs.2011.02.017 10.1037/pha0000272 10.1016/j.freeradbiomed.2013.12.026 10.1124/jpet.105.085779 10.1016/0165-0173(93)90013-P 10.1007/BF00431988
Journal of General Internal Medicine; Balachandran P, Elsohly M et. al.

Jan 30th, 2021 - Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a broad range of disorders. Recently, there has been increased interest in CBD, as several studies showed promising anticonvulsant efficacy with few side effe...

MRI-guided stereotactic laser corpus callosotomy for epilepsy: distinct methods and out...
https://doi.org/10.3171/2020.7.JNS20498
Journal of Neurosurgery; Rich CW, Fasano RE et. al.

Jan 22nd, 2021 - Several small series have described stereotactic MRI-guided laser interstitial thermal therapy for partial callosotomy of astatic and generalized tonic-clonic (GTC) seizures, especially in association with Lennox-Gastaut syndrome. Larger case seri...

see more →

Drugs  819 results see all →

Clinicaltrials.gov  1,657 results

The role of surgery in the management of Lennox-Gastaut syndrome: A systematic review a...
https://doi.org/10.1111/epi.16851
Epilepsia Thirunavu V, Du R et. al.

Feb 24th, 2021 - Lennox-Gastaut syndrome (LGS) is a severe form of childhood onset epilepsy in which patients require multiple medications and may be candidates for palliative surgical intervention. In this meta-analysis, we sought to evaluate the impact of pallia...

The efficacy and tolerability of auto-stimulation-VNS in children with Lennox-Gastaut s...
https://doi.org/10.1016/j.seizure.2021.02.015
Seizure Abdelmoity SA, Abdelmoity AA et. al.

Feb 24th, 2021 - Lennox-Gastaut syndrome (LGS) is a severe drug-resistant epilepsy (DRE) of childhood. The Vagus Nerve Stimulator (VNS) is established as a safe and effective treatment for DRE. This study assesses efficacy and tolerability of the auto-stimulation ...

Lamotrigine - lamotrigine tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff16760e-5604-4dd5-9ab8-5614eec39a10

Feb 23rd, 2021 - Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1) Epilepsy—monotherapy in patien...

Topiramate - topiramate tablet-NuCare Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=490f109f-30cb-0790-e054-00144ff88e88

Feb 22nd, 2021 - Topiramate tablets USP is an antiepileptic (AED) agent indicated for: Monotherapy epilepsy: Initial monotherapy in patients ≥ 2 years of age with partial onset or primary generalized tonic-clonic seizures ( 1.1) Adjunctive therapy epilepsy: Adjunc...

Topiramate - topiramate tablet-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99496bc5-bd88-7ca4-e053-2995a90a7bc0

Feb 21st, 2021 - Topiramate tablets are indicated for: Epilepsy: initial monotherapy in patients ≥2 years of age with partial onset or primary generalized tonic-clonic seizures ( 1.1); adjunctive therapy for adults and pediatric patients (2 to 16 years of age) wit...

see more →

News  115 results

FDA Approves Cannabidiol for Tuberous Sclerosis Complex
https://www.staging.medscape.com/viewarticle/935067

Aug 2nd, 2020 - The cannabidiol (CBD) oral solution Epidiolex has been approved by the US Food and Drug Administration (FDA) for the new indication of treatment of seizures associated with tuberous sclerosis complex in patients 1 year of age and older. The drug w...

FDA Approves Cannabidiol for Tuberous Sclerosis Complex
https://www.medscape.com/viewarticle/935067

Aug 2nd, 2020 - The cannabidiol (CBD) oral solution Epidiolex has been approved by the US Food and Drug Administration (FDA) for the new indication of treatment of seizures associated with tuberous sclerosis complex in patients 1 year of age and older. The drug w...

Cannabis Medicine Available for Severe Epilepsy in New Year
https://www.medscape.com/viewarticle/923042

Dec 22nd, 2019 - Thousands of people in England with a severe form of epilepsy will have access to cannabidiol (Epidyolex, GW Pharma) from the New Year as adjunctive therapy for seizures. The treatment for Lennox-Gastaut syndrome or Dravet syndrome, in conjunction...

Cannabis Medicine Available for Severe Epilepsy in New Year
https://www.staging.medscape.com/viewarticle/923042

Dec 22nd, 2019 - Thousands of people in England with a severe form of epilepsy will have access to cannabidiol (Epidyolex, GW Pharma) from the New Year as adjunctive therapy for seizures. The treatment for Lennox-Gastaut syndrome or Dravet syndrome, in conjunction...

Rare Pediatric Diseases Special Report 2019
https://www.mdedge.com/pediatrics/article/211163/rare-diseases/rare-pediatric-diseases-special-report-2019?channel=167

Oct 29th, 2019 - The Rare Pediatric Diseases Special Report is a supplement to Pediatric News that discusses advancements in the treatment of rare pediatric neuromuscular disorders like spinal muscular atrophy, Duchenne muscular dystrophy, and X-linked myotubular.

see more →